PRESTIGE® with HAVLOGEN®

Horses

Therapeutic Class

Equine Rhinopneumonitis Vaccine


Description
A combination of inactivated, purified, concentrated, adjuvanted, equine tissue culture origin Equine Herpesvirus EHV-1 and EHV-4.

Indications
For vaccination of healthy horses, 6 months of age or older, as an aid in the control of respiratory diseases caused by Equine Herpesvirus.

Administration and Dosage
For primary immunization, aseptically inject 1 mL intramuscularly. Repeat the dose in 4 to 6 weeks. A 1 mL dose should be administered annually and at any time epidemic conditions exist or are reported and exposure is imminent.

Caution
Store at 35o to 45o F (2o to 7oC). Shake well before using. Do not vaccinate within 21 days before slaughter. Local reactions may occur if this product is given subcutaneously. Inject deep into the muscle only. Anaphylactoid reactions may occur.

Antidote
Epinephrine. Neomycin, polymyxin B, nystatin and thimerosal added as preservatives.

Supplied
Code: 069140
10 mL (10 doses) vial.

Product Label(s) and MSDS

For more information about Merck Animal Health Products call 1-800-441-8272.